New data from the phase 3 help study open-label extension evaluate the long-term safety and efficacy of takhzyro® (lanadelumab) in reducing hereditary angioedema attacks

Takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced findings from two new interim analyses of data from the phase 3 h
ETNB Ratings Summary
ETNB Quant Ranking